New Treatment Option for High Blood Pressure Available to U.S. Veterans

High blood pressure, often called the "silent killer," is a grave health concern that affects millions, particularly veterans. Uncontrolled hypertension can lead to severe health complications, including heart disease and stroke, making its effective management paramount. Recent advancements in medical treatment provide hope for those struggling with this condition, particularly veterans who often face unique health challenges.

In 2023, the Veterans Health Administration (VHA) indicated that approximately 66% of veterans suffering from hypertension do not have their condition under control, defining uncontrolled hypertension as blood pressure readings above or equal to 130/90 mmHg. Traditional treatments have often begun with lifestyle changes, such as dietary adjustments and increased physical activity, along with prescribed medications. However, data shows that around one-third of patients remain uncontrolled even after these interventions. For these individuals, solar-technology-based medical device therapies offer a compelling alternative.

The recent partnership between Recor Medical and Recon Supply introduces the Paradise Ultrasound Renal Denervation (uRDN) system specifically designed to treat hypertension among veterans effectively. This innovative device offers a minimally invasive procedure that has been clinically proven to lower blood pressure, making it a potential game changer in hypertension management.

One veteran who has benefited from this revolutionary treatment is Richard Van Name, an Army pilot with over 30 years of service. Upon his retirement, Richard was diagnosed with hypertension and faced challenges in managing his condition despite his commitment to lifestyle changes and medication. His blood pressure remained dangerously high, prompting his doctor to recommend the Paradise uRDN treatment, a strategy that amplifies the body's response to reducing blood pressure.

Richard's experience underscores the transformative power of this new technology. "My blood pressure was starting to creep up in the last part of my career, with readings of 178 over 100 at diagnosis. I tried various medications and lifestyle changes, yet my blood pressure hovered around 150 to 160. After the ultrasound renal denervation procedure, I felt a significant improvement, easing the concern of heart attacks or strokes," he shared.

The Paradise uRDN system functions by targeting the sympathetic nerves surrounding the renal arteries. By employing ultrasound energy, the device works to deactivate the nerve signals that contribute to hypertension. This process consists of delivering two to three ultrasound bursts, each lasting for seven seconds, to the renal arteries, thanks to its unique HydroCooling™ feature that protects the artery during treatment. Supported by several professional medical societies, including the American Heart Association, this treatment is an exciting new avenue for those veterans experiencing difficulty with conventional hypertension management options.

With a firm commitment to improving the health of veterans, Recor Medical has emphatically dedicated itself to advancing hypertension treatment options for over a decade, culminating in the recent FDA approval of the Paradise system. This breakthrough came after three rigorous clinical studies demonstrating the efficacy and safety of the device. Furthermore, to gather long-term data on its impact, Recor is launching the US Global Paradise System (GPS) Post-Approval Study aimed at observing 1,000 patients across the nation.

For veterans facing the challenge of hypertension, the Paradise uRDN system offers renewed hope and an alternative to traditional treatments that may not be effective. As healthcare continues to evolve, innovations like this underscore the importance of addressing the specific health needs of veterans, ensuring they receive the best possible care tailored to their circumstances.

For more information regarding treatment eligibility and potential risks associated with the Paradise system, healthcare professionals will conduct thorough assessments to guide patients effectively. Possible risks may include mild discomfort and complications at the access site, but many agree that the potential for substantial improvements in health far outweighs these considerations.

In conclusion, the availability of the Paradise Ultrasound Renal Denervation system represents a significant advancement in the management of hypertension among U.S. veterans. In changing lives, it heralds a hopeful future for managing this silent but potentially deadly condition.